A recent phase 3 study published in The Lancet revealed that the experimental drug orforgliprona is more effective than oral semaglutide in achieving glucose control and weight loss for individuals with type 2 diabetes. The trial involved 1,698 adult participants over 52 weeks and compared the effects of orforgliprona at doses of 12 mg and 36 mg to semaglutida at doses of 7 mg and 14 mg. The results showed that patients taking orforgliprona lost an average of 8.9 kg, representing a relative weight loss of 73.6% more than those on semaglutida, who lost an average of 5.0 kg.

In addition to the significant weight loss, the study found that orforgliprona reduced glucose levels by 2.2%, compared to a 1.4% reduction for semaglutide. This indicates that orforgliprona not only supports weight loss but also contributes to better glycemic control, which is crucial for managing type 2 diabetes. Both drugs were assessed based on primary and secondary outcomes, with orforgliprona outperforming semaglutida in all analyzed metrics.

These findings could have important implications for diabetes treatment, as effective weight management is a key factor in managing type 2 diabetes. If approved for broader use, orforgliprona could represent a valuable option for patients seeking better outcomes than those currently offered by existing medications like semaglutide.